The firm will issue 7mln shares of common stock at US$6 each for total gross proceeds of approximately US$42mln
() said that its portfolio company LogicBio Therapeutics, Inc. (NASDAQ: LOGC), has announced the pricing of its underwritten public offering in the US.
Venture capital company Arix said it has agreed to invest $3mln in the offering and retains a stake of 9.4% in LogicBio.
LogicBio will issue 7mln shares of common stock at US$6 each for total gross proceeds of approximately US$42mln, before deducting underwriting discounts and commissions and offering expenses.
In addition, LogicBio has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of common stock, at the public offering price less underwriting discounts and commissions.
The offering is expected to close on October 5.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE